Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Brielle Urciuoli
In recent years, immunotherapy has been falling flat in the brain cancer field, but recent research may change that.
Kristie L. Kahl
Patients who receive anti-PD-1 therapies may experience delayed cutaneous side effects like lesions, eczema or psoriasis, even after treatment has ended.
Kristie L. Kahl
In this week’s episode of CURE® Talks Cancer, we delve into immunotherapy breakthroughs and how a new series of patient summits can help individuals learn more.
Jessica Skarzynski
Take a look at the top five CURE stories of July 2018 in this video. 
Jessica Skarzynski
Because little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments, the researchers performed a systematic review and meta-analysis to determine the heterogeneity of immune checkpoint inhibitor efficacy between men and women.
Brielle Urciuoli
What are the different types of immunotherapy and, importantly, what are fellow patients saying about them?
Kristie L. Kahl
We spoke with veteran journalist Neil Canavan about his book, A Cure Within: Scientists Unleashing the Immune System to Kill Cancer. 
Checkpoint inhibitors — immunotherapy drugs that are improving the treatment landscape for many patients across the spectrum of cancers — are relatively new. The science involved in finding and treating the patients most likely to respond to these drugs — without overlooking any or treating those who won’t benefit — is even newer. 
We've known for over a century about rare patients who experience spontaneous regressions of cancer. We don’t have absolute proof, but, presumably, this occurs because their immune systems are able to rally and fight the disease.
Beth Fand Incollingo
Stand Up To Cancer’s “interception” trials tackle lung and pancreatic disease early, with the goal of preventing progression to advanced stages.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other